1. Временные методические рекомендации Минздрава России «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Москва, 2020. Версия 7 (03.06.2020)». Available from: https://static0.rosminzdrav.ru/system/attachments/attaches/000/050/584/original/03062020_%D0%9CR_COVID-19_v7.pdf. [Temporary methodological recommendations of Ministry of health of Russia “Prevention, diagnosis and treatment of the new coronavirus infection (COVID-19). Moscow, 2020. Version 7(03.06.2020)”. Available from: https://static0.rosminzdrav.ru/system/attachments/attaches/000/050/584/original/03062020_%D0%9CR_COVID-19_v7.pdf. In Russian].
2. Baig AM, Khaleeq A, Ali U, et al. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, hostvirus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci. 2020;11(7):995–998.
3. Palasca O, Santos A, Stolte C, et al. TISSUES 2.0: an integrative web resource on mammalian tissue expression [published correction appears in Database (Oxford). 2018 Jan 1;2018]. Database (Oxford). 2018;2018:bay003.
4. Li Y, Li H, Fan R, et al. Coronavirus infections in the central nervous system and respiratory tract show distinct features in hospitalized children. Intervirology. 2016;59(3):163–169.
5. Niu J, Shen L, Huang B, et al. Non-invasive bioluminescence imaging of HCoV-OC43 infection and therapy in the central nervous system of live mice. Antiviral Res. 2020;173:104646.
6. Li K, Wohlford-Lenane C, Perlman S, et al. Middle East respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4. J Infect Dis. 2016;213(5):712–722.
7. Netland J, Meyerholz DK, Moore S, et al. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol. 2008;82(15):7264–7275.
8. Chan JF, Chan KH, Choi GK, et al. Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation. J Infect Dis. 2013;207(11):1743–1752.
9. Desforges M, Miletti TC, Gagnon M, et al. Activation of human monocytes after infection by human coronavirus 229E. Virus Res. 2007;130(1–2):228–240.
10. Li J, Gao J, Xu YP, et al. [Expression of severe acute respiratory syndrome coronavirus receptors, ACE2 and CD209L in different organ derived microvascular endothelial cells]. Zhonghua Yi Xue Za Zhi. 2007;87(12):833–837.
11. Li YC, Bai WZ, Hirano N, et al. Neurotropic virus tracing suggests a membranous-coating-mediated mechanism for transsynaptic communication. J Comp Neurol. 2013;521(1):203–212.
12. Benussi A, Pilotto A, Premi E, et al. Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia, Lombardy, Italy [published online ahead of print, 2020 May 22]. Neurology. 2020;10.1212/WNL.0000000000009848.
13. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China [published online ahead of print, 2020 Apr 10]. JAMA Neurol. 2020;77(6):1–9.
14. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [published correction appears in Lancet. 2020 Jan 30;:]. Lancet. 2020;395(10223):497–506.
15. Deng Y, Liu W, Liu K, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study. Chin Med J (Engl). 2020;133(11):1261–1267.
16. Li LQ, Huang T, Wang YQ, et al. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020;92(6):577–583.
17. González-Pinto T, Luna-Rodríguez A, Moreno- Estébanez A, et al. Emergency room neurology in times of COVID-19: malignant ischaemic stroke and SARS-CoV-2 infection [published online ahead of print, 2020 Apr 30]. Eur J Neurol. 2020;10.1111/ene.14286.
18. Beyrouti R, Adams ME, Benjamin L, et al. Characteristics of ischaemic stroke associated with COVID-19 [published online ahead of print, 2020 Apr 30]. J Neurol Neurosurg Psychiatry. 2020;jnnp-2020-323586.
19. Al Saiegh F, Ghosh R, Leibold A, et al. Status of SARS-CoV-2 in cerebrospinal fluid of patients with COVID-19 and stroke [published online ahead of print, 2020 Apr 30]. J Neurol Neurosurg Psychiatry. 2020;jnnp-2020-323522.
20. Oxley TJ, Mocco J, Majidi S, et al. Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young. N Engl J Med. 2020;382(20):e60.
21. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med. 2020;382(17):e38.
22. Lushina N, Kuo JS, Shaikh HA. Pulmonary, Cerebral, and Renal Thromboembolic Disease Associated with COVID-19 Infection [published online ahead of print, 2020 Apr 23]. Radiology. 2020;201623.
23. Zhai P, Ding Y, Li Y. The impact of COVID-19 on ischemic stroke: a case report. Res Sq. 2020.
24. Sharifi-Razavi A, Karimi N, Rouhani N. COVID-19 and intracerebral haemorrhage: causative or coincidental? New Microbes New Infect. 2020;35:100669.
25. Moshayedi P, Ryan TE, Mejia LLP, et al. Triage of acute ischemic stroke in confirmed COVID-19: large vessel occlusion associated with coronavirus infection. Front Neurol. 2020;11:353.
26. Li Y. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. SSRN Electron J. 2020.
27. Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9–14.
28. Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020;382(23):2268–2270.
29. Filatov A, Sharma P, Hindi F, et al. Neurological complications of coronavirus disease (COVID-19): Encephalopathy. Cureus. 2020;12(3):e7352.
30. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study [published correction appears in BMJ. 2020 Mar 31;368:m1295]. BMJ. 2020;368:m1091.
31. Poyiadji N, Shahin G, Noujaim D, et al. COVID-19- associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features [published online ahead of print, 2020 Mar 31]. Radiology. 2020;201187.
32. Zhou L, Zhang M, Wang J, et al. Sars-CoV-2: Underestimated damage to nervous system [published online ahead of print, 2020 Mar 24]. Travel Med Infect Dis. 2020;101642.
33. Ye M, Ren Y, Lv T. Encephalitis as a clinical manifestation of COVID-19 [published online ahead of print, 2020 Apr 10]. Brain Behav Immun. 2020;S0889-1591(20)30465-7.
34. Pilotto A, Odolini S, Masciocchi S, et al. Steroidresponsive encephalitis in coronavirus disease 2019 [published online ahead of print, 2020 May 17]. Ann Neurol. 2020;10.1002/ana.25783.
35. Moriguchi T, Harii N, Goto J, et al. A first case of meningitis/encephalitis associated with SARSCoronavirus-2. Int J Infect Dis. 2020;94:55–58.
36. Duong L, Xu P, Liu A. Meningoencephalitis without respiratory failure in a young female patient with COVID-19 infection in Downtown Los Angeles, early April 2020. Brain Behav Immun. 2020;87:33.
37. Bernard-Valnet R, Pizzarotti B, Anichini A, et al. Two patients with acute meningo-encephalitis concomitant to SARS-CoV-2 infection. medRxiv 2020.
38. Zhao K, Huang J, Dai D, et al. Acute myelitis after SARS-CoV-2 infection: a case report. medRxiv 2020.
39. Yan CH, Faraji F, Prajapati DP, et al. Association of chemosensory dysfunction and COVID-19 in patients presenting with influenza-like symptoms [published online ahead of print, 2020 Apr 12]. Int Forum Allergy Rhinol. 2020;10.1002/alr.22579.
40. Bagheri SH, Asghari AM, Farhadi M, et al. Coincidence of COVID-19 epidemic and olfactory dysfunction outbreak. medRxiv 2020.
41. Alberti P, Beretta S, Piatti M, et al. Guillain-Barré syndrome related to COVID-19 infection. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e741.
42. Padroni M, Mastrangelo V, Asioli GM, et al. Guillain-Barré syndrome following COVID-19: new infection, old complication? [published online ahead of print, 2020 Apr 24]. J Neurol. 2020;1–3.
43. Virani A, Rabold E, Hanson T, et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection [published online ahead of print, 2020 Apr 18]. IDCases. 2020;20:e00771.
44. Camdessanche JP, Morel J, Pozzetto B, et al. COVID-19 may induce Guillain-Barré syndrome. Rev Neurol (Paris). 2020;176(6):516–518.
45. Sedaghat Z, Karimi N. Guillain Barre syndrome associated with COVID-19 infection: A case report. J Clin Neurosci. 2020;76:233–235.
46. Zhao H, Shen D, Zhou H, et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol. 2020;19(5):383–384.
47. Toscano G, Palmerini F, Ravaglia S, et al. Guillain-Barré syndrome associated with SARS-CoV-2. N Engl J Med. 2020;382(26):2574–2576.
48. Gutiérrez-Ortiz C, Méndez A, Rodrigo-Rey S, et al. Miller Fisher syndrome and polyneuritis cranialis in COVID-19 [published online ahead of print, 2020 Apr 17]. Neurology. 2020;10.1212/WNL.0000000000009619.
49. Jacomy H, Fragoso G, Almazan G, et al. Human coronavirus OC43 infection induces chronic encephalitis leading to disabilities in BALB/C mice. Virology. 2006;349(2):335–346.